In addition, our proteogenomics analyses identified significant associations of genetic variants with levels of complement proteins in plasma, adjusted for AMD status, sex and age: FHR-2 peptide levels were associated with AMD variants at the CFH locus, C4 peptide levels were associated with an AMD variant at the C2/CFB/SKIV2L locus, VTN peptide levels were associated with an AMD variant at the TMEM97/VTN locus, FI peptide levels were associated with AMD variants at the CFI locus and C9 peptide levels were associated with an AMD variant at the C9 locus. This evidence concerns the gene C2 and age-related macular degeneration.